📣 VC round data is live. Check it out!
- Public Comps
- CellaVision
CellaVision Valuation Multiples
Discover revenue and EBITDA valuation multiples for CellaVision and similar public comparables like Semler Scientific, Humacyte, Abbott Pakistan, SmartVest and more.
CellaVision Overview
About CellaVision
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.
Founded
1994
HQ

Employees
236
Website
Financials (LTM)
EV
$287M
Valuation Multiples
Start free trialCellaVision Financials
CellaVision reported last 12-month revenue of $84M and EBITDA of $26M.
In the same LTM period, CellaVision generated $57M in gross profit, $26M in EBITDA, and $17M in net income.
Revenue (LTM)
CellaVision P&L
In the most recent fiscal year, CellaVision reported revenue of $84M and EBITDA of $27M.
CellaVision is profitable as of last fiscal year, with gross margin of 66%, EBITDA margin of 32%, and net margin of 20%.
Financial data powered by Morningstar, Inc.
CellaVision Stock Performance
CellaVision has current market cap of $309M, and enterprise value of $287M.
Market Cap Evolution
CellaVision's stock price is $12.96.
CellaVision share price decreased by 1.5% in the last 30 days, and by 33.9% in the last year.
CellaVision has an EPS (earnings per share) of $0.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $287M | $309M | -0.7% | -1.5% | -22.8% | -33.9% | $0.72 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCellaVision Valuation Multiples
CellaVision trades at 3.4x EV/Revenue multiple, and 10.9x EV/EBITDA.
EV / Revenue (LTM)
CellaVision Financial Valuation Multiples
As of June 3, 2026, CellaVision has market cap of $309M and EV of $287M.
CellaVision has a P/E ratio of 18.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CellaVision Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


CellaVision Margins & Growth Rates
CellaVision grew revenue by 0% but EBITDA decreased by 4% in the last fiscal year.
In the most recent fiscal year, CellaVision reported gross margin of 66%, EBITDA margin of 32%, and net margin of 20%.
CellaVision Margins
CellaVision Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
CellaVision Operational KPIs
CellaVision's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
CellaVision's Rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CellaVision's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
CellaVision Competitors
CellaVision competitors include Semler Scientific, Humacyte, Abbott Pakistan, SmartVest, Medipost, Shoulder Innovations, NIOX Group, 908 Devices, Ascom and Advanced Technology Company.
Most CellaVision public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| 161.0x | 83.7x | (14.8x) | - | |||
| 1.0x | - | 4.9x | - | |||
| 4.5x | 3.9x | 20.4x | 16.7x | |||
| 5.2x | - | (4.8x) | - | |||
| 4.2x | 3.5x | (5.4x) | (5.9x) | |||
| 4.6x | 4.6x | 13.6x | 13.2x | |||
| 4.0x | 3.7x | (23.7x) | (28.2x) | |||
This data is available for Pro users. Sign up to see all CellaVision competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CellaVision
| When was CellaVision founded? | CellaVision was founded in 1994. |
| Where is CellaVision headquartered? | CellaVision is headquartered in Sweden. |
| How many employees does CellaVision have? | As of today, CellaVision has over 236 employees. |
| Who is the CEO of CellaVision? | CellaVision's CEO is Simon Ostergaard. |
| Is CellaVision publicly listed? | Yes, CellaVision is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of CellaVision? | CellaVision trades under CEVI ticker. |
| When did CellaVision go public? | CellaVision went public in 2007. |
| Who are competitors of CellaVision? | CellaVision main competitors include Semler Scientific, Humacyte, Abbott Pakistan, SmartVest, Medipost, Shoulder Innovations, NIOX Group, 908 Devices, Ascom, Advanced Technology Company. |
| What is the current market cap of CellaVision? | CellaVision's current market cap is $309M. |
| What is the current revenue of CellaVision? | CellaVision's last 12 months revenue is $84M. |
| What is the current revenue growth of CellaVision? | CellaVision revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of CellaVision? | Current revenue multiple of CellaVision is 3.4x. |
| What is the current EBITDA of CellaVision? | CellaVision's last 12 months EBITDA is $26M. |
| What is CellaVision's EBITDA margin? | CellaVision's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of CellaVision? | Current EBITDA multiple of CellaVision is 10.9x. |
| What is the current FCF of CellaVision? | CellaVision's last 12 months FCF is $12M. |
| What is CellaVision's FCF margin? | CellaVision's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of CellaVision? | Current FCF multiple of CellaVision is 23.0x. |
| How many companies CellaVision has acquired to date? | CellaVision hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies CellaVision has invested to date? | CellaVision hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to CellaVision
Lists including CellaVision
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.